EN DE
Watch Episurf Medical AB (publ) for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Episurf Medical AB (publ) (EPIS-B) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Episurf Medical AB (publ) stock SEK 0.06, price SEK 0.06, that is 6.2% below the price, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0003491562

EM Episurf Medical AB (publ) logo Thin data Nov 10, 2026

Episurf Medical AB (publ)

EPIS-B · ST
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value kr 0.0582 · Fairly valued
Expensive Growth (revenue 5y +22.0 %/yr in SEK)
Quality 33/100
Negative free cash flow
Trails peers (3/8)
Narrow moat 35/100 · thin data
Thin data
Estimate
Watch Episurf Medical AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 5.68 kr 0.0274 Fair Value kr 0.0582 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.0274 – kr 5.68 · fair‑value band kr 0.0495 – kr 0.0669 · the kr 0.0620 price screens above the kr 0.0582 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Episurf Medical AB (publ) in your weekly email

Every Wednesday you see whether Episurf Medical AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally.

Show moreShow less

It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint.

The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning.

In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot.

Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient's distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient.

The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Stock analysis

Episurf Medical AB (publ) (EPIS-B) currently trades at kr 0.0620, while our estimate is kr 0.0582, so the stock looks roughly fairly valued today (gap 6.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.0495 (bear) to kr 0.0669 (bull), the price of kr 0.0620 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Episurf Medical AB (publ) reported revenue of 13.5M SEK in FY2025 versus 6.5M SEK in FY2021, a compound +20.0%/yr. Reported net income was −58.2M SEK in FY2025.

Key figures

Market cap 961M SEK (≈ $97.4M) Micro · P/S ratio 36.8 · EPS (TTM) kr −0.0700 · Return on equity −91.1% · Return on assets (EBIT) −67.1% (5-year average) · Operating margin 65.9% · Revenue (TTM) 26.1M SEK · Revenue growth (YoY) +413%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 126% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −6%, EPIS-B screens richer than that median.

Fair Value

Bear kr 0.0495 Fair Value kr 0.0582 Bull kr 0.0669
Price kr 0.0620 · Downside -6.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 60
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
Start year 2020 (pandemic). Over 10 years: +29.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,278.0% (2020) → −447.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EPIS-B, get fair value alerts →

Compare Episurf Medical AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −6.1% · Above median
Profitability
Return on assets −97.3% · Bottom 25%
Operating margin (12 months) 65.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 412.5% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 20.22× · Priciest 25%
P/S (12 months) 36.80× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs EPIS-B
DexCom, Inc DXCM $79.92 $89.18 +12% vs EPIS-B
Stryker Corporation SYK $324.29 $358.30 +10% vs EPIS-B
STERIS plc STE $257.12 $279.53 +9% vs EPIS-B
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs EPIS-B
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs EPIS-B
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs EPIS-B
Abbott Laboratories, ABT $110.46 $75.28 −32% vs EPIS-B
Medtronic plc MDT $101.59 $65.61 −35% vs EPIS-B
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs EPIS-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Episurf Medical AB (publ): fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Episurf Medical AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/EPIS-B

Frequently asked questions

Is Episurf Medical AB (publ) (EPIS-B) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.0582 versus a price of kr 0.0620, about 6% lower (fairly valued).
What is the fair value of EPIS-B?
Our estimate for Episurf Medical AB (publ) is kr 0.0582 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.0620.
What is the quality score of EPIS-B?
Episurf Medical AB (publ) has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Episurf Medical AB (publ) (EPIS-B)?
Our calculated price target is the estimate of kr 0.0582 (as of Nov 10, 2026). Cautious scenario kr 0.0495, optimistic scenario kr 0.0669. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Episurf Medical AB (publ) stock forecast for 2026?
Our estimate puts fair value at kr 0.0582, about 6% lower versus a price of kr 0.0620 (fairly valued). Cautious scenario kr 0.0495, optimistic scenario kr 0.0669. The calculation is refreshed regularly with new filings.
What is the revenue of Episurf Medical AB (publ) (EPIS-B)?
Episurf Medical AB (publ) reported trailing-twelve-month revenue of about 26.1M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Episurf Medical AB (publ) (EPIS-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Episurf Medical AB (publ) it is kr 0.0582 per share (as of Nov 10, 2026), against a price of kr 0.0620.
Is Episurf Medical AB (publ) stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EPIS-B trades above its calculated fair value: price kr 0.0620, fair value kr 0.0582, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPIS-B?
No. The price is what the market pays today (kr 0.0620); the fair value is what the company's own numbers justify (kr 0.0582). For Episurf Medical AB (publ) the two are kr 0.0038 per share apart. That gap is exactly why we show both numbers side by side.
How much is Episurf Medical AB (publ) worth?
The market values Episurf Medical AB (publ) at about 961M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.0620; our models calculate a fair value of kr 0.0582 per share.
What do the bullish and bearish scenarios say about EPIS-B?
Our models span a range for Episurf Medical AB (publ): cautious scenario kr 0.0495, base kr 0.0582, optimistic kr 0.0669 per share (as of Nov 10, 2026, price kr 0.0620). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Episurf Medical AB (publ) (EPIS-B)?
Balance-sheet figures for Episurf Medical AB (publ) (as of Nov 10, 2026): return on equity −91.1%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is EPIS-B from its 52-week high?
Episurf Medical AB (publ) trades at kr 0.0620, about 69% below its 52-week high of kr 0.2000 and 126% above the low of kr 0.0274 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0582 is for.
Which stocks are comparable to Episurf Medical AB (publ)?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Episurf Medical AB (publ) stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.0620, calculated fair value kr 0.0582 (−6%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Episurf Medical AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Episurf Medical AB (publ) (EPIS-B)?
The closing price on Nov 10, 2026 was kr 0.0620. Our estimate is kr 0.0582, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Episurf Medical AB (publ) right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Episurf Medical AB (publ)

How large is the market capitalisation of Episurf Medical AB (publ) (EPIS-B)?
The market capitalisation of Episurf Medical AB (publ) is 961M SEK (≈ $97.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Episurf Medical AB (publ) (EPIS-B)?
The price-to-sales ratio of Episurf Medical AB (publ) is 36.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Episurf Medical AB (publ) (EPIS-B)?
Earnings per share at Episurf Medical AB (publ) are kr −0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Episurf Medical AB (publ) (EPIS-B)?
The return on equity (ROE) of Episurf Medical AB (publ) is −91.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Episurf Medical AB (publ) (EPIS-B)?
On an EBIT basis the return on assets of Episurf Medical AB (publ) is −67.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Episurf Medical AB (publ) (EPIS-B)?
The operating margin of Episurf Medical AB (publ) is 65.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Episurf Medical AB (publ) (EPIS-B)?
Revenue at Episurf Medical AB (publ) is growing +413% versus a year earlier (3y avg +26.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Episurf Medical AB (publ) (EPIS-B) generate?
The free cash flow of Episurf Medical AB (publ) is −62.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Episurf Medical AB (publ) (EPIS-B) hold?
Episurf Medical AB (publ) holds more cash than debt, 300K SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Episurf Medical AB (publ) in the live analysis

One click puts Episurf Medical AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.